Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accounts Payables (2016 - 2025)

Enanta Pharmaceuticals' Accounts Payables history spans 14 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 60.11% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, down 60.11%, while the annual FY2025 figure was $1.9 million, 75.66% down from the prior year.
  • Accounts Payables reached $1.9 million in Q4 2025 per ENTA's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.8 million in Q1 2023 to a low of $1.2 million in Q2 2022.
  • Average Accounts Payables over 5 years is $6.1 million, with a median of $5.9 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: plummeted 78.88% in 2022, then surged 537.11% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $7.8 million in 2021, then tumbled by 44.5% to $4.4 million in 2022, then surged by 114.29% to $9.3 million in 2023, then plummeted by 49.32% to $4.7 million in 2024, then plummeted by 60.11% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Accounts Payables are $1.9 million (Q4 2025), $1.9 million (Q3 2025), and $3.5 million (Q2 2025).